Search research articles
Contact Us
Filters
Showing results (41-50 of 453) with videos related to
Page
of 46
Sort By:
Oncology (Williston Park, N.Y.)
|
June 21, 2013
Treatment recommendations for anaplastic oligodendrogliomas that are codeleted
Mark D Anderson, Mark R Gilbert
Current Neurology and Neuroscience Reports
|
June 11, 2008
Use of complementary and alternative medical therapy by patients with primary brain tumors
Terri S Armstrong, Mark R Gilbert
Nature Clinical Practice. Neurology
|
January 6, 2007
Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy?
Mark R Gilbert, Frederick F Lang
Expert Review of Anticancer Therapy
|
May 12, 2007
Molecularly targeted therapies for malignant gliomas: advances and challenges
Marta Penas-Prado, Mark R Gilbert
Current Oncology Reports
|
November 17, 2010
Patient profiling for treatment toxicity: potential use of clinical and genomic factors
Terri S Armstrong, Mark R Gilbert
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 10, 2014
Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted)
Mark D Anderson, Mark R Gilbert
Journal of Neuro-Oncology
|
February 29, 2020
Glucocorticoids and immune checkpoint inhibitors in glioblastoma
William J Kelly, Mark R Gilbert
Neuro-Oncology
|
March 19, 2016
Creating clinical trial designs that incorporate clinical outcome assessments
Mark R Gilbert, Lawrence Rubinstein, Glenn Lesser
Cancer Control : Journal of the Moffitt Cancer Center
|
April 25, 2003
Advances in molecular therapies in patients with brain tumors
Ivo W Tremont-Lukats, Mark R Gilbert
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
December 21, 2016
Toward Personalized Targeted Therapeutics: An Overview
Shiao-Pei S Weathers, Mark R Gilbert
Page
of 46
Search research articles
Search
Showing results (41-50 of 453) with videos related to
Sort By:
Page
of 46
Oncology (Williston Park, N.Y.)
|
June 21, 2013
Treatment recommendations for anaplastic oligodendrogliomas that are codeleted
Mark D Anderson, Mark R Gilbert
Current Neurology and Neuroscience Reports
|
June 11, 2008
Use of complementary and alternative medical therapy by patients with primary brain tumors
Terri S Armstrong, Mark R Gilbert
Nature Clinical Practice. Neurology
|
January 6, 2007
Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy?
Mark R Gilbert, Frederick F Lang
Expert Review of Anticancer Therapy
|
May 12, 2007
Molecularly targeted therapies for malignant gliomas: advances and challenges
Marta Penas-Prado, Mark R Gilbert
Current Oncology Reports
|
November 17, 2010
Patient profiling for treatment toxicity: potential use of clinical and genomic factors
Terri S Armstrong, Mark R Gilbert
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 10, 2014
Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted)
Mark D Anderson, Mark R Gilbert
Journal of Neuro-Oncology
|
February 29, 2020
Glucocorticoids and immune checkpoint inhibitors in glioblastoma
William J Kelly, Mark R Gilbert
Neuro-Oncology
|
March 19, 2016
Creating clinical trial designs that incorporate clinical outcome assessments
Mark R Gilbert, Lawrence Rubinstein, Glenn Lesser
Cancer Control : Journal of the Moffitt Cancer Center
|
April 25, 2003
Advances in molecular therapies in patients with brain tumors
Ivo W Tremont-Lukats, Mark R Gilbert
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
December 21, 2016
Toward Personalized Targeted Therapeutics: An Overview
Shiao-Pei S Weathers, Mark R Gilbert
Page
of 46